Condition: Myelodysplastic Syndromes · Higher Risk Myelodysplastic Syndromes · Acute Myeloid Leukemia · Sponsor: Remix Therapeutics
The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with Higher Risk MDS and relapsed/refractory AML
This description comes directly from the study's public registry record.
Remix Therapeutics · 781-827-0902 · ClinicalTrials@remixtx.com
Rosalie Jiang · 781-584-9390 · rjiang@remixtx.com
Always discuss trial participation with your own doctor first.
| City of Hope | Duarte, California, United States | Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| Memorial Sloan Kettering | New York, New York, United States | Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| Centre Hospitalier Universitaire (CHU) de Bordeaux | Bordeaux, France | Recruiting |
| AP-HP - Hôpital Saint-Louis | Paris, France | Recruiting |
| IUCT-Oncopole | Toulouse, France | Recruiting |
| Institut de Cancerologie Gustave-Roussy | Villejuif, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06297941